Markets Stocks Economy Crypto Earnings Banking Energy
Home Tech Feature
Breaking · Tech

Pasqal's Nasdaq debut lifts quantum stocks, but use cases remain elusive

Pasqal's Nasdaq debut lifts quantum stocks, but use cases remain elusive
Tech · 2026
Photo · Eleanor Whitfield for Daily Digest Invest
By Eleanor Whitfield Markets Editor-in-Chief Aug 28, 2026 5 min read

Quantum computing is back in the spotlight after French startup Pasqal made its Nasdaq debut through a SPAC merger that valued the company at roughly $2 billion. Shares surged as much as 73% in early trading before settling to about 40% higher, according to Reuters. The pop is a reminder that investors remain hungry for exposure to a technology that promises to revolutionise computing — even if the industry has yet to deliver a definitive, money-making application.

What is Pasqal and why does it matter?

Pasqal is a Paris-based company that builds quantum computers using neutral atoms, a technology that uses lasers to trap and manipulate individual atoms to perform calculations. Unlike classical computers, which process information as bits (0s and 1s), quantum computers use qubits that can exist in multiple states at once, potentially allowing them to solve certain problems far faster than today's machines.

The company's arrival on the Nasdaq via a SPAC — a special purpose acquisition company, which is a shell company that raises money and merges with a private firm to take it public — is a notable milestone. It gives everyday investors a way to buy into a pure-play quantum company, a rare opportunity in a field dominated by giants like IBM, Google, and Microsoft, which all have quantum research programs but also many other businesses.

The quantum hype cycle

Quantum computing has been a recurring theme in tech investing for years, with periodic waves of excitement followed by reality checks. The sector's promise is enormous: quantum machines could one day crack encryption, discover new drugs, optimise supply chains, and model complex chemical reactions. But the technology is still in its infancy, and no one has yet demonstrated a quantum computer that can outperform a classical computer on a commercially valuable task — a milestone often called "quantum advantage."

That hasn't stopped investors from bidding up quantum-related stocks. Pasqal's debut echoes earlier rallies in other quantum names, such as IonQ and Rigetti Computing, which went public via SPACs in 2021 and saw their shares soar before later pulling back. The pattern is familiar: a headline-grabbing listing sparks a surge of interest, but the underlying business fundamentals — revenue, profitability, and a clear path to market — often remain thin.

What this means for investors

For the average investor, Pasqal's debut is a double-edged sword. On one hand, it's an exciting sign that cutting-edge technology is becoming accessible through public markets. On the other, it's a high-risk bet on a company that is still years away from generating meaningful revenue, let alone profits. The 73% intraday jump, followed by a pullback to 40%, illustrates the kind of volatility that comes with speculative tech stocks.

Investors should also consider the broader context. The SPAC route has a mixed track record: many companies that went public via SPACs during the 2020-2021 boom have struggled, and some have even faced delisting or bankruptcy. Pasqal's $2 billion valuation is a big number for a company that, according to public reports, has yet to achieve a clear commercial breakthrough. That doesn't mean it won't succeed, but it does mean the risk is substantial.

The hunt for a use case

The biggest question hanging over the entire quantum sector is simple: what will these machines actually be used for? While researchers have made impressive strides in the lab, the industry is still searching for a "killer app" — a problem that quantum computers can solve better, faster, or cheaper than classical computers in a way that customers will pay for.

Some companies are already selling access to quantum computers via the cloud, and others are working on hybrid approaches that combine classical and quantum processing. But the timeline for widespread commercial adoption remains uncertain, with estimates ranging from a few years to a decade or more. For now, quantum computing is more of a research and development story than a revenue story.

What to watch next

For investors tracking Pasqal and its peers, the key metrics to watch are not just stock price movements but also customer announcements, partnerships, and technical milestones. Any news of a quantum computer solving a real-world problem — such as optimising a logistics network or simulating a new battery material — could send the sector soaring again. Conversely, a major technical setback or a high-profile failure could cool the enthusiasm just as quickly.

In the meantime, the broader market backdrop matters too. Tech stocks have been sensitive to interest rate expectations, as seen in recent moves tied to Federal Reserve signals. A shift in the rate outlook could affect how investors value speculative, long-duration assets like quantum computing companies. For a sense of how such macro forces are playing out, keep an eye on rate-sensitive markets and currency moves.

The bottom line

Pasqal's Nasdaq debut is a milestone for the quantum computing industry, putting the technology back on the radar of everyday investors. But it's worth remembering that a stock's first-day pop doesn't guarantee long-term success. The sector is still in its early days, and the path from scientific promise to profitable business is long and uncertain. As with any speculative investment, it's wise to do your own research and consider how much risk you're comfortable with.

For those who believe in the long-term potential of quantum computing, Pasqal's listing offers a new way to participate. But for those who prefer more established businesses, the sector's volatility might be a reason to watch from the sidelines. Either way, the quantum story is far from over — and the next chapter could be written sooner than you think.

More from this story

Next article · Don't miss

Chip and pharma projects could lift US factory construction above $200B

UBS expects US factory construction to rebound, led by new chip and pharma projects. Manufacturing-related building could top $200 billion by end of next year after a recent slowdown.

Read the story →
Chip and pharma projects could lift US factory construction above $200B